What is Ogivri™ (trastuzumab-dkst)?

Ogivri is a targeted treatment used to treat certain people with metastatic breast cancer that is positive for the human epidermal growth factor receptor 2 (HER2+). It is used for HER2+ metastatic breast cancer:1,2

  • In combination with paclitaxel as a first-line treatment
  • Alone in people who have received 1 or more chemotherapy drugs for metastatic breast cancer

Metastatic breast cancer is cancer that has spread to other parts of the body, such as the bones or liver. Breast cancer tumors are defined as HER2+ or HER2- cancers. HER2 refers to a specific protein that appears on the surface of cancer cells and makes the cells multiply faster. When cancer cells produce too many HER2 molecules, they are called HER2+ tumors.1,2

Ogivri is a biosimilar to Herceptin® (trastuzumab). Drugs similar in structure to known biologic drugs are called biosimilars.1,2

What is the active ingredient in Ogivri?

The active ingredient in Ogivri is trastuzumab-dkst.1

How does Ogivri work?

Ogivri is a monoclonal antibody. Antibodies are a normal part of the immune system that attach to antigens (such as germs) to mark them for destruction by other components in the immune system. Monoclonal antibodies are created in a laboratory to attach to specific antigens on the surface of cancer cells.1

Breast cancers that are classified as HER2+ have too many HER2 receptor antigens. This can cause the cancer to grow and spread quickly. Ogivri targets these receptors and can slow or block the growth and spread of HER2+ breast cancers.1

What are the possible side effects of Ogivri?

The most common side effects of Ogivri include:1

  • Fever
  • Chills
  • Headache
  • Infection
  • Trouble sleeping
  • Cough
  • Rash
  • Diarrhea
  • Nausea

Ogivri has a boxed warning, the strictest warning from the U.S. Food and Drug Administration (FDA). This is because it may cause:

  • Heart problems, such as congestive heart failure or reduced heart function
  • Infusion reactions, which may cause fever, chills, nausea, vomiting, pain, headache, dizziness, and/or shortness of breath
  • Serious harm to an unborn baby, which may cause birth defects or death
  • Severe lung damage
  • Worsening of chemotherapy-induced reductions in white blood cells

These are not all the possible side effects of Ogivri. Talk to your doctor about what to expect or if you experience any changes that concern you during treatment with Ogivri.

Things to know about Ogivri

Your doctor will monitor your heart function before and during treatment with Ogivri.1

Ogivri can harm an unborn baby. If you or your partner can become pregnant, you should use birth control during treatment and for some time after the last dose of Ogivri. You should also not breastfeed during treatment with Ogivri and for some time after the last dose. Talk to your doctor about your options for birth control and breastfeeding while taking Ogivri.1

Before beginning treatment for breast cancer, tell your doctor about all your health conditions and any other drugs, vitamins, or supplements you are taking. This includes over-the-counter drugs.

For more information, read the full prescribing information of Ogivri.

By providing your email address, you are agreeing to our privacy policy. We never sell or share your email address.

More on this topic

Written by: Editorial Team | Last reviewed: March 2021